Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Wayne F. Pisano M.B.A. | Interim CEO & Chairman of the Board | 82.16k | -- | 1955 |
| Mr. Kirk J. Look C.A., CA | Chief Financial Officer | 563.27k | -- | -- |
| Dr. Matthew C. Coffey M.B.A., Ph.D. | President, CEO & Director (Leave of Absence) | 806k | -- | -- |
| Dr. Thomas C. Heineman M.D., Ph.D. | Chief Medical Officer | 620.47k | -- | -- |
| Ms. Allison Hagerman P.Eng., P.M.P. | Vice President of Product Development | 427.89k | -- | -- |
| Ms. Amy Goodowitz Levin B.S.N., R.N. | Vice President of Clinical Operations | 412.25k | -- | -- |
| Jon Patton | Director of Investor Relations & Communication | -- | -- | -- |
| Mr. John Mark Lievonen B.B.A., F.C.A., FCPA, LLD, M.B.A. | Consultant | 19.31k | -- | -- |
Oncolytics Biotech Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Corporate Governance
Upcoming Events
March 5, 2025 at 10:59 AM UTC - March 10, 2025 at 12:00 PM UTC
Oncolytics Biotech Inc. Earnings Date
Recent Events
August 5, 2024 at 12:00 AM UTC
SUPPL: Voluntary supplemental material filed pursuant to Section 11(a) of the Securities Act of 1933 by foreign issuers